| Scleroderma |
1 |
1 |
| Biologic Therapy |
0 |
0.72 |
| Pulmonary Arterial Hypertension |
0 |
0.66 |
| Systemic Sclerosis |
0 |
0.99 |
| Heart Failure (HF) |
0 |
0.49 |
| Interstitial Lung Disease |
0 |
0.49 |
| Lung |
0 |
0.47 |
| Lung Fibrosis |
0 |
0.44 |
| Hypertension |
0 |
0.42 |
| Monoclonal Antibody |
0 |
0.39 |
| Antineoplastic Drug |
0 |
0.31 |
| Pulmonary Hypertension |
0 |
0.31 |
| Europe |
0 |
0.23 |
| Raynaud Phenomenon |
0 |
0.23 |
| Disease-Modifying Antirheumatic Drugs |
0 |
0.15 |
| Immunosuppressive Therapy |
0 |
0.15 |
| Idiopathic Pulmonary Fibrosis |
0 |
0.14 |
| Rheumatoid Arthritis |
0 |
0.14 |
| Endothelin Receptor Antagonists |
0 |
0.11 |
| Clinical Guidelines |
0 |
0.08 |
| Crisis Intervention |
0 |
0.08 |
| Fellowship |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Immunocompromise |
0 |
0.08 |
| NHS |
0 |
0.08 |
| Nonpharmacologic |
0 |
0.08 |
| Receptors |
0 |
0.08 |